Seeing Is Believing
Currently out of the existing stock ratings of Daniel Brims, 8 are a BUY (88.89%), 1 are a HOLD (11.11%).
Analyst Daniel Brims, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 66.67% that have a potential upside of 11.8% achieved within 40 days. Previously, Daniel Brims worked at HCWAINWRIGHT.
Daniel Brims’s has documented 17 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TTPH, Tetraphase Pharmaceuticals at 09-Sep-2015.
Analyst best performing recommendations are on TTPH (TETRAPHASE PHARMACEUTICALS).
The best stock recommendation documented was for TTPH (TETRAPHASE PHARMACEUTICALS) at 9/9/2015. The price target of $220 was fulfilled within 9 days with a profit of $30.2 (15.91%) receiving and performance score of 17.68.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
4 years 6 months 14 days ago
(07-May-2020)
1/2 (50%)
$36.05 (72.09%)
304
Buy
$140
5 years 2 months 18 days ago
(03-Sep-2019)
0/4 (0%)
$69.6 (98.86%)
Buy
$380
5 years 6 months 11 days ago
(10-May-2019)
0/3 (0%)
$224.8 (144.85%)
Buy
6 years 2 months 1 days ago
(20-Sep-2018)
0/3 (0%)
$150.4 (116.05%)
Buy
$140
$137.8 (6263.64%)
$120
6 years 2 months 24 days ago
(28-Aug-2018)
0/3 (0%)
$81.4 (104.62%)
What Year was the first public recommendation made by Daniel Brims?